Abstract: Compounds of formula (I): wherein Het1, Het2, R1, R2 and R3 are as defined in the description.

Abstract: Compounds of formula (I): wherein Het, Het1, Het2, A4, A5, Z1, R1, R2 and R3 defined in the description. Medicaments.

Abstract: Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termination codons with one or more compounds or compositions described herein.

Abstract: Method for treating a disease, condition, or syndrome in a subject comprising administering, to a subject in need thereof, a solid or liquid pharmaceutical composition comprising: (a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F or G; and (b) a surfactant; wherein the composition does not comprise albumin or a polysaccharide.

Abstract: Compounds of formula (I): wherein Het, Het1, Het2, A4, A5, Z1, R1, R2 and R3 are as defined in the description. Medicaments.

Abstract: Compounds of formula (I): wherein Het1, Het2, R1, R2 and R3 are as defined in the description.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Integrated mounting systems for mounting electric drive components within electrified vehicles may include a cross brace assembly that mounts or supports one or more electric drive components relative to a vehicle frame. A cross brace assembly of the mounting system may include a cross brace, a first bridging side bracket, and a second bridging side bracket. The cross brace may be mounted to lower surfaces of vehicle frame rails and the bridging side brackets may be mounted to upper surfaces of the vehicle frame rails to provide a robust and serviceable mounting solution that evenly distributes vehicle loads.

Abstract: A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:

Abstract: This disclosure details integrated mounting systems for mounting electric drive components within electrified vehicles. An exemplary mounting system may include a cross brace assembly that mounts or supports one or more electric drive components relative to a vehicle frame. A cross brace assembly of the mounting system may include a cross brace, a first bridging side bracket, and a second bridging side bracket. The cross brace may be mounted to lower surfaces of vehicle frame rails and the bridging side brackets may be mounted to upper surfaces of the vehicle frame rails to provide a robust and serviceable mounting solution that evenly distributes vehicle loads.

Abstract: A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:

Abstract: Method for treating a disease, condition, or syndrome in a subject comprising administering, to a subject in need thereof, a solid or liquid pharmaceutical composition comprising: (a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F or G; and (b) a surfactant; wherein the composition does not comprise albumin or a polysaccharide.

Abstract: Solid and liquid pharmaceutical compositions comprising botulinum neurotoxin complex or high purity botulinum neurotoxin and a surfactant. The composition may comprise a crystalline agent.

Abstract: A portable lifting arm includes a base, a plurality of casters fixed to a bottom side of the base, an arm mounting structure extending upward from a top side of the base, and an arm. The arm includes a first arm segment having a first end and a second end, the first end of the first arm segment being attached to the arm mounting structure, a second arm segment having a first end and second end, the first end of the second arm segment rotationally connected to the second end of the first arm segment, and a power tool rotationally connected to the second end of the second arm segment. A controller in electrical communication the power tool selects between predetermined settings on the power tool based on a position of the first arm segment and the second arm segment relative to the arm mounting structure.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: A portable lifting arm includes a base, a plurality of casters fixed to a bottom side of the base, an arm mounting structure extending upward from a top side of the base, and an arm. The arm includes a first arm segment having a first end and a second end, the first end of the first arm segment being attached to the arm mounting structure, a second arm segment having a first end and second end, the first end of the second arm segment rotationally connected to the second end of the first arm segment, and a power tool rotationally connected to the second end of the second arm segment. A controller in electrical communication the power tool selects between predetermined settings on the power tool based on a position of the first arm segment and the second arm segment relative to the arm mounting structure.

Abstract: A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:

Abstract: A door garnish mounting device for a mounting a door garnish to a door of a vehicle includes a frame, door alignment arms extending from the frame, and a garnish applicator mounted to the frame. The door alignment arms having datum points configured to engage corresponding vehicle datum points of the vehicle proximate to a mounting location of the door garnish to the vehicle to align the frame with the door of the vehicle. The garnish applicator includes a pressing device configured to engage and press against the door garnish, a first actuator configured to press the pressing device against the door garnish, and a second actuator configured to move the pressing device along the door garnish.

Abstract: Low molecular weight polyoxyalkylene polyether polyols having a hydroxyl content of from about 3.4 to about 12.1% by weight, and OH numbers of from about 112 to about 400 are produced by a continuous process using a DMC catalyst. In the process of the present invention, oxyalkylation conditions are established in a continuous reactor in the presence of a DMC catalyst; alkylene oxide and a low molecular weight starter are continuously introduced into the continuous reactor; a partially oxyalkylated polyether polyol is recovered from the reactor; and the recovered partially oxyalkylated polyether polyol is allowed to further reactor until the unreacted alkylene oxide content of the mixture is reduced to 0.001% or less by weight. The alkoxylation of the present invention must be carried out a pressure sufficiently high to prevent deactivation of the DMC catalyst. Pressures of from 45 to 55 psia are preferred.